Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Overview of attention for article published in New England Journal of Medicine, March 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

So far, Altmetric has seen 30 news stories from 21 outlets.

Early, permanent discontinuation of venetoclax in the treatment of relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL…

Patients now have multiple options, including continuous therapy with BTK inhibitors and fixed-duration therapy with venetoclax-b…

Updated efficacy outcomes of the phase 3 MURANO trial demonstrated that fixed-duration venetoclax plus rituximab is an…

A fixed-duration of venetoclax (Venclexta) plus rituximab (Rituxan) led to sustained and durable responses in patients with…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 26 additional news stories.